The University of California San Francisco Comprehensive Cancer Center is an NCI-designed matrix center conducting a wide range of inter-disciplinary research in the areas of laboratory, clinical and population sciences integrating the activities of 223 members working at 4 major campus and hospital locations. Its goals are to: (1) support cancer research of the highest possible quality, in the areas of laboratory, clinical and population sciences;(2) develop patient outreach and education programs to increase the value of the Center to the local community;(3) promote and develop first-class care for cancer patient in our affiliated hospitals;and (4) create an integrated community of investigators dedicated to the shared goal of translating innovative science into improved clinical care. These goals are accomplished through the following 11 Programs and 12 Shared Resources: Programs Shared Resources -------------- ---------------------------- Breast Cancer Laboratory for Cell Analysis Neurologic Oncology Genome Analysis Cancer &Immunity Array Prostate Cancer Tissue Society, Diversity &Disparities Immunohistochemistry and Molecular Pathology Pancreas Cancer Transgenic/Targeted Mutagenesis Hematopoietic Malignancies Informatics Pediatric Malignancies Mouse Pathology Cell Cycling and Signaling Preclinical Therapeutics Cancer Genetics Mass Spectrometry Tobacco Control Biostatistics Clinical Research Support Services

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-13
Application #
8133069
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1999-08-05
Project End
2012-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
13
Fiscal Year
2011
Total Cost
$7,206,672
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications